Skip to main content
Universe Pharmaceuticals INC logo

Universe Pharmaceuticals INC — Investor Relations & Filings

Ticker · UPC ISIN · KYG9442G1047 US Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2020-09-23 Capital/Financing Update
Country US United States of America
Listing US UPC

About Universe Pharmaceuticals INC

http://www.universe-pharmacy.com/

Universe Pharmaceuticals INC is a pharmaceutical company specializing in the manufacturing, marketing, sales, and distribution of traditional Chinese medicine (TCM) derivative products. Through its subsidiaries, the company's product portfolio also includes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements.

Recent filings

Filing Released Lang Actions
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'Free Writing Prospectus' and is filed pursuant to Rule 433 of the Securities Act of 1933. It relates to a proposed public offering of ordinary shares by Universe Pharmaceuticals INC. The text includes detailed information about the offering, use of proceeds, company background, product descriptions, and risk factors. It references a Registration Statement on Form F-1 and provides links to the SEC filings. The content is clearly related to capital raising and financing activities, specifically an initial public offering (IPO). This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, nor is it a presentation or regulatory filing unrelated to financing. Therefore, the appropriate classification is CAP with high confidence.
2020-09-23 English
Regulatory Filings 2020
Regulatory Filings
2020-09-01 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a letter from Universe Pharmaceuticals Inc. responding to comments from the SEC staff regarding a Draft Registration Statement on Form F-1. It references amendments to a registration statement and discusses internal controls and risk factor disclosures. The letter is a correspondence related to regulatory review and does not contain financial statements or detailed financial data. It is not a full report like an Annual Report or Interim Report, nor is it an earnings release or other financial filing. The document is a regulatory correspondence responding to SEC comments, which fits best under Regulatory Filings (RNS). The document length is short (2139 characters), and it is clearly a letter rather than a report or announcement of a report publication.
2020-08-17 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for an initial public offering (IPO) of ordinary shares by Universe Pharmaceuticals Inc. The text includes detailed information about the offering, underwriting, risk factors, management, and financial data, typical of a registration prospectus. This type of filing is related to capital raising and financing activities, specifically the registration of securities for public sale. Therefore, it fits the category of Capital/Financing Update (CAP). The document is not an annual report, earnings release, or any other report type but a registration statement for securities offering.
2020-08-17 English
Regulatory Filings 2020
Regulatory Filings
2020-06-24 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from Universe Pharmaceuticals Inc. to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on a Draft Registration Statement on Form F-1. The letter addresses specific SEC comments, revisions made to the registration statement, and clarifications on corporate structure, risk factors, financial disclosures, and other regulatory compliance matters. The presence of references to Form F-1, SEC staff comments, and detailed regulatory disclosures indicates this is a regulatory filing related to a securities registration process, not a financial report, earnings release, or other types of filings. The document is not a report publication announcement but a substantive response to SEC comments. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-06-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.